替格瑞洛联合经皮冠状动脉介入术在冠心病合并房颤患者中的应用

Abstract
Figure/Table
References (19)
Related Citation (15)

Download: PDF (0 KB) HTML (38 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To explore the application of Ticagrelor combined with percutaneous coronary intervention(PCI)in patients with coronary heart disease complicated with atrial fibrillation.Methods Seventy patients with coronary heart disease complicated with atrial fibrillation admitted to Chancheng District Central Hospital of Foshan City from January 2019 to June 2020 were selected as the research objects.According to the random number table method,they were divided into an observation group and a control group,with 35 cases in each group.Both groups were treated with PCI surgery.The control group was treated with Clopidogrel Bisulfate,and the observation group was treated with Ticagrelor.The course of treatment for both groups was one month.The changes of serum index levels,platelet levels and atrial fibrillation episodes before and after treatment were compared between the two groups.Results Before treatment,there were no significant differences in serum indexes levels between the two groups(P>0.05).The levels of hypersensitivity C-reactive protein(hs-CRP),creatine kinase isoenzyme(CK-MB),myoglobin and B-type brain natriuretic peptide(BNP)after treatment in the two group were lower than those before treatment,with statistically significant differences(P<0.05).After treatment,the levels of hs-CRP,CK-MB,myoglobin and BNP in the observation group were lower than those in the control group,with statistically significant differences(P<0.05).There were no significant differences in the levels of maximum platelet aggregation rate(MPA)or platelet response index(PRI)between the two groups before treatment(P>0.05).The MPA levels of the two groups after treatment were lower than those before treatment,with statistically significant differences(P<0.05).The PRI level of the observation group after treatment was higher than that before treatment,with statistically significant difference(P<0.05).After treatment,MPA level in the observation group was lower than that in the control group,and PRI level was higher than that in the control group,with statistically significant differences(P<0.05).After six months of treatment,the observation group had fewer episodes of atrial fibrillation than the control group,the duration of episodes was shorter than that of the control group,and the ST-segment depression during the episode was lower than that of the control group,with statistically significant differences(P<0.05).Conclusion Ticagrelor combined with PCI in the treatment of coronary heart disease complicated with atrial fibrillation can effectively improve the patients′ serum levels,and has a significant anticoagulant effect,which helps to reduce the formation of thrombosis.

Key words： Ticagrelor Percutaneous coronary intervention Clopidogrel Anticoagulant

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	CHEN Tian-hai
	LIU Kai-dong
	ZENG Hai-long

Cite this article:

CHEN Tian-hai,LIU Kai-dong,ZENG Hai-long. Application of Ticagrelor combined with percutaneous coronary intervention in patients with coronary heart disease complicated with atrial fibrillation[J]. 中国当代医药, 2021, 28(25): 80-83.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2021/V28/I25/80

[1]	黄从新，张澍，黄德嘉，等.心房颤动：目前的认识和治疗的建议-2018[J].中国心脏起搏与心电生理杂志，2018，32（4）：315-369.
[2]	钱军，陈建峰，王丽洁，等.冠心病合并持续性心房颤动患者抗栓方案的研究[J].中华心律失常学杂志，2018，22（3）：215-221.
[3]	张智文，杨海涛.心房颤动患者经皮冠状动脉介入治疗后的抗栓疗法研究进展[J].中国心血管病研究，2019，17（2）：114-117.
[4]	张广求，张美祥，王树平.新型口服抗凝药物适应症及指南推荐意见[J].实用心脑肺血管病杂志，2018，26（9）：1-5
[5]	徐汝明，马丽萍.替格瑞洛影响冠心病患者血浆腺苷浓度的研究进展[J].第二军医大学学报，2019，40（6）：664-667.
[6]	Xing J，Liu Y，Chen T.Correlations of chemokine CXCL16 and TNF-α with coronary atherosclerotic heart disease[J].Exp Ther Med，2018，15（1）：773-776.
[7]	刘培健，王玉林，何杏仪.替格瑞洛与氯吡格雷对老年冠心病患者血清同型半胱氨酸、超敏C 反应蛋白、白细胞介素-6 水平的影响[J].中国老年学杂志，2020，40（5）：909-912.
[8]	来桂棵，朱丽，赵一品，等.替格瑞洛与氯吡格雷对冠状动脉三支病变介入治疗患者住院期间及长期临床结果比较[J].现代预防医学，2019，46（16）：3049-3052，3056.
[9]	赵忠平，丁晓云，罗正义.冠心病合并心房颤动患者PCI术后出血风险预测列线图的构建及验证[J].心脑血管病防治，2020，20（6）：553-556.
[10]	冠心病合并心房颤动患者抗栓管理中国专家共识[J].中华心血管病杂志，2020，48（7）：552-564.
[11]	周坤，张国茹，王亚玲，等.冠心病合并房颤的老年患者PCI 术后抗栓治疗的安全性和有效性[J].中国老年学杂志，2019，39（3）：529-531.
[12]	张欣.负荷剂量替格瑞洛对于急性心梗PCI 后血清炎性因子、心肌酶与冠脉血流的影响[J].心血管康复医学杂志，2020，29（2）：163-167.
[13]	刘岳，任怡荣，朱火兰，等.新型口服抗凝药物在非瓣膜性心房颤动患者中的应用及挑战[J].中国全科医学，2020，23（23）：2872-2876，2894.
[14]	孙沙沙，陈薇，胡家宾，等.新型口服抗凝药在冠心病患者中的研究进展[J].中华老年心脑血管病杂志，2019，21（6）：664-665.
[15]	梁多才.替格瑞洛与氯吡格雷治疗急性冠状动脉综合征患者的临床疗效对比[J].中国医药指南，2020，18（35）：137-138，141.
[16]	王嵩亮，黄涛，徐静.替格瑞洛治疗经皮冠状动脉介入患者时对凝血功能及血小板聚集的改善效果[J].中国现代医生，2020，58（33）：115-117.
[17]	吴刚，唐黎.替格瑞洛联合阿司匹林对冠心病患者血小板活化功能、炎性因子水平及凝血功能的影响[J].临床合理用药杂志，2021，14（1）：48-49.
[18]	李万.采用替格瑞洛联合阿司匹林治疗不稳定型心绞痛的疗效探究[J].北方药学，2020，17（3）：42-43.
[19]	李刚，王立静，龙会平，等.急性冠状动脉综合征经皮冠状动脉介入后应用替格瑞洛疗效观察[J].现代中西医结合杂志，2019，28（22）：2447-2449.